(Q35212543)

English

The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

cardiovascular disease

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

author name string

Willa A Hsueh

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Ronald Law

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

1 August 2003

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

4A

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

3J-9J

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Insulin signalling and the regulation of glucose and lipid metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Signaling pathways in insulin action: molecular targets of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

New perspectives into the molecular pathogenesis and treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

You are what you secrete

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Resistin and obesity-associated insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Forum One: Current recommendations about intensification of metabolic control in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Diabetes mellitus and genetically programmed defects in beta-cell function

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Assessment of hepatic insulin action in obese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

The relation of body fat mass and distribution to markers of chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Body fatness and fat distribution as predictors of metabolic abnormalities and early carotid atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Effect of a single high-fat meal on endothelial function in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Inflammatory pathways in atherosclerosis and acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Cytokines as emerging targets in the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Cardiovascular risk factors and the prediabetic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

High sensitivity C-reactive protein for predicting cardiovascular disease: an inflammatory hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Adverse endothelial function and the insulin resistance syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Biochemistry and molecular cell biology of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Protein kinase C activation and the development of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Coronary artery disease: the Scandinavian Simvastatin Survival Study experience

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Peroxisome proliferator-activated receptor gamma and metabolic disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

trans-10,cis-12-Conjugated linoleic acid reduces leptin secretion from 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

PPARgamma and atherosclerosis: effects on cell growth and movement

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900610-6

7 January 2021

Identifiers

10.1016/S0002-9149(03)00610-6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35212543&oldid=1946658301"